Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers (Revenue from Customers by Products) (Details)

v3.24.1.u1
Revenue from Contracts with Customers (Revenue from Customers by Products) (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]        
Revenues $ 4,135,301 $ 6,585,967 $ 6,276,027 $ 9,093,761
FC2 [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 4,135,301 6,580,447 6,276,027 9,080,448
FC2, Global Public Health Sector [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 3,537,994 2,434,287 5,045,001 4,771,284
FC2, U.S. Prescription Channel [Member]        
Disaggregation of Revenue [Line Items]        
Revenues $ 597,307 4,146,160 $ 1,231,026 4,309,164
ENTADFI [Member]        
Disaggregation of Revenue [Line Items]        
Revenues   $ 5,520   $ 13,313